144 related articles for article (PubMed ID: 34674982)
21. Dual color FISH on CBF primary acute myeloid leukemia.
Sorour A; Nafea D
Egypt J Immunol; 2008; 15(2):25-31. PubMed ID: 20306685
[TBL] [Abstract][Full Text] [Related]
22. Both the subtypes of KIT mutation and minimal residual disease are associated with prognosis in core binding factor acute myeloid leukemia: a retrospective clinical cohort study in single center.
Duan W; Liu X; Zhao X; Jia J; Wang J; Gong L; Jiang Q; Zhao T; Wang Y; Zhang X; Xu L; Shi H; Chang Y; Liu K; Huang X; Qin Y; Jiang H
Ann Hematol; 2021 May; 100(5):1203-1212. PubMed ID: 33474629
[TBL] [Abstract][Full Text] [Related]
23. High IL2RA mRNA expression is an independent adverse prognostic biomarker in core binding factor and intermediate-risk acute myeloid leukemia.
Du W; He J; Zhou W; Shu S; Li J; Liu W; Deng Y; Lu C; Lin S; Ma Y; He Y; Zheng J; Zhu J; Bai L; Li X; Yao J; Hu D; Gu S; Li H; Guo A; Huang S; Feng X; Hu D
J Transl Med; 2019 Jun; 17(1):191. PubMed ID: 31171000
[TBL] [Abstract][Full Text] [Related]
24. Core-binding factor acute myeloid leukemia: Heterogeneity, monitoring, and therapy.
Solh M; Yohe S; Weisdorf D; Ustun C
Am J Hematol; 2014 Dec; 89(12):1121-31. PubMed ID: 25088818
[TBL] [Abstract][Full Text] [Related]
25. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype.
Breems DA; Van Putten WL; De Greef GE; Van Zelderen-Bhola SL; Gerssen-Schoorl KB; Mellink CH; Nieuwint A; Jotterand M; Hagemeijer A; Beverloo HB; Löwenberg B
J Clin Oncol; 2008 Oct; 26(29):4791-7. PubMed ID: 18695255
[TBL] [Abstract][Full Text] [Related]
26. A >or=1 log rise in RQ-PCR transcript levels defines molecular relapse in core binding factor acute myeloid leukemia and predicts subsequent morphologic relapse.
Lane S; Saal R; Mollee P; Jones M; Grigg A; Taylor K; Seymour J; Kennedy G; Williams B; Grimmett K; Griffiths V; Gill D; Hourigan M; Marlton P
Leuk Lymphoma; 2008 Mar; 49(3):517-23. PubMed ID: 18297529
[TBL] [Abstract][Full Text] [Related]
27. Prognostic Significance of KIT Mutations in Core-Binding Factor Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis.
Chen W; Xie H; Wang H; Chen L; Sun Y; Chen Z; Li Q
PLoS One; 2016; 11(1):e0146614. PubMed ID: 26771376
[TBL] [Abstract][Full Text] [Related]
28. Comprehensive mutational profiling of core binding factor acute myeloid leukemia.
Duployez N; Marceau-Renaut A; Boissel N; Petit A; Bucci M; Geffroy S; Lapillonne H; Renneville A; Ragu C; Figeac M; Celli-Lebras K; Lacombe C; Micol JB; Abdel-Wahab O; Cornillet P; Ifrah N; Dombret H; Leverger G; Jourdan E; Preudhomme C
Blood; 2016 May; 127(20):2451-9. PubMed ID: 26980726
[TBL] [Abstract][Full Text] [Related]
29. Core binding factor (CBF) acute myeloid leukemia: is molecular monitoring by RT-PCR useful clinically?
Marcucci G; Caligiuri MA; Bloomfield CD
Eur J Haematol; 2003 Sep; 71(3):143-54. PubMed ID: 12930314
[TBL] [Abstract][Full Text] [Related]
30. Different prognostic effects of core-binding factor positive AML with Korean AML registry data.
Shin HJ; Min WS; Min YH; Cheong JW; Lee JH; Kim IH; Hong DS; Ahn JS; Kim HJ; Lee WS; Jung CW; Jang JH; Park Y; Kim HJ;
Ann Hematol; 2019 May; 98(5):1135-1147. PubMed ID: 30758645
[TBL] [Abstract][Full Text] [Related]
31. Core-binding factor acute myeloid leukemia.
Sangle NA; Perkins SL
Arch Pathol Lab Med; 2011 Nov; 135(11):1504-9. PubMed ID: 22032582
[TBL] [Abstract][Full Text] [Related]
32. Heterogeneity in CBF beta/MYH11 fusion messages encoded by the inv(16)(p13q22) and the t(16;16)(p13;q22) in acute myelogenous leukemia.
Shurtleff SA; Meyers S; Hiebert SW; Raimondi SC; Head DR; Willman CL; Wolman S; Slovak ML; Carroll AJ; Behm F
Blood; 1995 Jun; 85(12):3695-703. PubMed ID: 7780153
[TBL] [Abstract][Full Text] [Related]
33. Prognosis and treatment outcome in patients with acute myeloid leukemia with t(8;21)(q22;q22).
Chen CC; Gau JP; Yu YB; Lu CH; Lee KD; You JY
Adv Ther; 2007; 24(4):907-20. PubMed ID: 17901040
[TBL] [Abstract][Full Text] [Related]
34. Molecular and clinical advances in core binding factor primary acute myeloid leukemia: a paradigm for translational research in malignant hematology.
Marcucci G; Caligiuri MA; Bloomfield CD
Cancer Invest; 2000; 18(8):768-80. PubMed ID: 11107447
[TBL] [Abstract][Full Text] [Related]
35. D816 mutation of the KIT gene in core binding factor acute myeloid leukemia is associated with poorer prognosis than other KIT gene mutations.
Yui S; Kurosawa S; Yamaguchi H; Kanamori H; Ueki T; Uoshima N; Mizuno I; Shono K; Usuki K; Chiba S; Nakamura Y; Yanada M; Kanda J; Tajika K; Gomi S; Fukunaga K; Wakita S; Ryotokuji T; Fukuda T; Inokuchi K
Ann Hematol; 2017 Oct; 96(10):1641-1652. PubMed ID: 28762080
[TBL] [Abstract][Full Text] [Related]
36. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.
Bloomfield CD; Lawrence D; Byrd JC; Carroll A; Pettenati MJ; Tantravahi R; Patil SR; Davey FR; Berg DT; Schiffer CA; Arthur DC; Mayer RJ
Cancer Res; 1998 Sep; 58(18):4173-9. PubMed ID: 9751631
[TBL] [Abstract][Full Text] [Related]
37. [Cytogentic and prognostic characteristic of acute myeloid leukemia with monosomal karyotype].
Li Z; Wei H; Lin D; Zhou CL; Liu BC; Wang Y; Liu KQ; Li W; Gong BF; Wei SN; Zhang GJ; Zhao XL; Li Y; Liu YT; Gong XY; Gu RX; Qiu SW; Mi YC; Wang JX
Zhonghua Xue Ye Xue Za Zhi; 2016 May; 37(5):366-71. PubMed ID: 27210869
[TBL] [Abstract][Full Text] [Related]
38. [Relationship between RAD51-g135C and XRCC3-C241T polymorphisms and prognosis of inv (16)/ t(16;16) (CBFbeta-MYH11) acute myeloid leukemia].
Liu L; Yang L; Mi YC; Li JY; Qin TJ; Xu ZF; Zhang Y; Wang JX; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2011 Jul; 32(7):433-8. PubMed ID: 22213860
[TBL] [Abstract][Full Text] [Related]
39. Allogeneic stem cell transplantation in second complete remission for core binding factor acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Halaburda K; Labopin M; Mailhol A; Socié G; Craddock C; Aljurf M; Beelen D; Cornelissen JJ; Bourhis JH; Labussière-Wallet H; Blaise D; Gedde-Dahl T; Gilleece M; Yakoub-Agha I; Mufti G; Esteve J; Mohty M; Nagler A
Haematologica; 2020 Jun; 105(6):1723-1730. PubMed ID: 31439677
[TBL] [Abstract][Full Text] [Related]
40. Comparison of therapy-related and de novo core binding factor acute myeloid leukemia: A bone marrow pathology group study.
Rogers HJ; Wang X; Xie Y; Davis AR; Thakral B; Wang SA; Borthakur G; Cantu MD; Margolskee EM; Philip JKS; Sukhanova M; Bagg A; Bueso-Ramos CE; Orazi A; Arber DA; Hsi ED; Hasserjian RP
Am J Hematol; 2020 Jul; 95(7):799-808. PubMed ID: 32249963
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]